Double-blind, randomized comparison of 24 weeks of norfloxacin and 12 weeks of norfloxacin followed by 12 weeks of placebo in the therapy of complicated urinary tract infection.

Abstract

We evaluated the benefits of prolonging norfloxacin therapy from 12 to 24 weeks for complicated urinary tract infection in a double-blind, randomized, placebo-controlled study. During the second 12 weeks, norfloxacin was superior to placebo (P less than 0.05) in suppressing bacteriuria. Adverse effects were common but mostly confined to the initial 12 weeks.

• Authors: G J Sheehan, G K Harding, D A Haase, M J Thomson, B Urias, J K Kennedy, D J Hoban, A R Ronald
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 32 Issue 8 Pg. 1292-3 (Aug 1988) ISSN: 0066-4804 [Print] United States
• PMID: 3056259 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Norfloxacin

Topics

• Bacteriuria (drug therapy)
• Clinical Trials as Topic
• Double-Blind Method
• Drug Administration Schedule
• Humans
• Norfloxacin (administration & dosage, adverse effects, therapeutic use)
• Prospective Studies
• Random Allocation
• Urinary Tract Infections (complications, drug therapy)